Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnipharDUB:UPR -0.12%73 3-Year EBITDA Growth Rate is 9.70% as of Dec. 2025, which is 52% below its 10-year median of 20.40. GuruFocus rates DUB:UPR with a GF Score™ of 73/100 and a GF Value™ of €3.68 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 105 Medical Distribution companies, Uniphar ranks better than 60.95% on this metric.
During the past 12 months, Uniphar's average EBITDA Per Share Growth Rate was -8.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 14.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Uniphar was 108.00% per year. The lowest was 6.30% per year. And the median was 20.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Uniphar 3-Year EBITDA Growth Rate Related Terms
DUB:UPR vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Uniphar's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Uniphar's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.70% mean?
Uniphar (DUB:UPR) has a 3-Year EBITDA Growth Rate of 9.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Uniphar and its competitors. This is 52% below median its historical median of 20.40. Over the past decade, Uniphar's 3-Year EBITDA Growth Rate has ranged from 6.30 to 108.00. According to the industry distribution chart, Uniphar ranks #41 out of 105 companies in the Medical Distribution industry, placing it in the top 39%.
Is Uniphar's 3-Year EBITDA Growth Rate too high?
Uniphar's current 3-Year EBITDA Growth Rate of 9.70% is 52% below median its 10-year median of 20.40. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 108.00. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. Uniphar's value of 9.70% is 79.6% above this industry median. Based on the distribution chart, Uniphar ranks #41 out of 105 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Uniphar has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #41 out of 105 companies for 3-Year EBITDA Growth Rate. This puts Uniphar in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.40. Uniphar's value of 9.70% is 79.6% above this benchmark. Historically, Uniphar's own 3-Year EBITDA Growth Rate has ranged from 6.30 to 108.00 over the past decade. While the company's 10-year median is 20.40 vs. the industry median of 5.40, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current 3-Year EBITDA Growth Rate of 9.70% is 79.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Uniphar and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current 3-Year EBITDA Growth Rate is 9.70%, which is 52% below median its own 10-year median of 20.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.68, compared to a current price of €4.27 — trading 16% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.70%, which is 52% below median its 10-year median of 20.40 and 79.6% above the Medical Distribution industry median of 5.40. Uniphar's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current 3-Year EBITDA Growth Rate is 9.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.27 is trading 16% above its estimated GF Value™ of €3.68.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
3-Year EBITDA Growth Rate: 9.70% (52% below median its 10-year median of 20.40)
GF Value™: €3.68 vs. price of €4.27 (16% above fair value)
Industry Position: 79.6% above the Medical Distribution median (#41 of 105)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
73GF Score
Get the complete analysis for DUB:UPR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
